Influential Analyst Rating Changes: CymaBay Therapeutics, Inc. (CBAY), Palatin Technologies, Inc. (PTN)

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) tinted gains of +0.42% (+0.04 points) to US$9.52. The volume of 0.56 Million shares climbed down over an trading activity of 631.53 Million shares. EPS ratio determined by looking at last 12 month figures is -1.04. Over the same time span, the stock marked US$15.59 as its best level and the lowest price reached was US$6.31. The corporation has a market cap of US$550.69 Million.

CymaBay Therapeutics, Inc. (NASDAQ:CBAY)’s earnings per share has been growing at a 17.7 percent rate over the past 5 year when average revenue increase was noted as 26.8 percent. The return on equity ratio or ROE stands at -34 percent while most common profitability ratio return on investment (ROI) was -23.4 percent. The company’s institutional ownership is monitored at 94.9 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 1 think it is Hold. Recently, analysts have updated the overall rating to 1.9. 7 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Palatin Technologies, Inc. (NYSE:PTN) is worth US$154.43 Million and has recently fallen -1.78% to US$0.76. The latest exchange of 0.53 Million shares is below its average trading activity of 945.96 Million shares. The day began at US$0.76 but the price moved to US$0.75 at one point during the trading and finally capitulating to a session high of US$0.77. The stock tapped a 52-week high of US$1.59 while the mean 12-month price target for the shares is US$4.58.

Currently, the stock carries a price to earnings ratio of 22.11, a price to book ratio of 6.45, and a price to sales ratio of 3.84. For the past 5 years, the company’s revenue has grown 478.5%, while the company’s earnings per share has grown 20.6%. With an institutional ownership near 21.8%, it carries an earnings per share ratio of 0.04.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 2 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.33.